Brainstorm Cell Therapeutics Files 8-K on Leadership Changes

TL;DR

Brainstorm Cell Therapeutics is shuffling its leadership team and executive compensation plans.

AI Summary

On June 19, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also includes information on compensatory arrangements for certain officers. Specific details regarding the individuals involved and the nature of these changes were not elaborated upon in the provided text.

Why It Matters

Changes in a company's board of directors and executive officers can signal shifts in strategy, operational focus, or financial health, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in executive and board composition can indicate underlying issues or strategic shifts that may affect the company's future performance and stability.

Key Players & Entities

• Brainstorm Cell Therapeutics Inc. (company) — Registrant
• June 19, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
• $73 million — 4, led BioCentriq from inception to its $73 million acquisition by GC Holdings (Korea), act
• $450,000 — es for an initial base annual salary of $450,000, an option to purchase 60,000 shares of
• $10,000 — one-time signing bonus of ten thousand ($10,000) U.S. Dollars, payable within 60 days o

Filing Documents

• tm2417625d1_8k.htm (8-K) — 31KB
• tm2417625d1_99-1.htm (EX-99.1) — 14KB
• 0001104659-24-073484.txt ( ) — 223KB
• bcli-20240619.xsd (EX-101.SCH) — 3KB
• bcli-20240619_lab.xml (EX-101.LAB) — 33KB
• bcli-20240619_pre.xml (EX-101.PRE) — 22KB
• tm2417625d1_8k_htm.xml (XML) — 4KB

02. Departure of Directors or Certain Officers Election

Item 5.02. Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers. On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the "Company") announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the "Start Date"). Dr. Hartounian, age 64, led BioCentriq from inception to its $73 million acquisition by GC Holdings (Korea), acting as its founder and serving as a member of its board of directors, as well as its Chief Executive Officer and President, from May 2022 to December 2023. He also served as BioCentriq's General Manager from June 2015 to May 2022. Prior to that, he co-founded DiaVacs and served as a member of its board of directors and as its Chief Executive Officer from February 2013 to April 2015. Additionally, he was the founder and Chief Executive Officer of Allied Bioventures from September 2011 to February 2013. From November 2008 to September 2011, he was Chief Executive Officer, President and a member of the board of directors of Vyteris Inc., where he led the company through a successful turnaround, reorganization, merger and business transformation, positioning it for growth and success in the Contract Research Organization industry. Further, Dr. Hartounian has been an affiliated faculty member at the New Jersey Institute of Technology in the Department of Chemistry and Environmental Sciences since April 2020, as well as an adjunct faculty member in the Department of Chemical Engineering at Columbia University from March 2015 to May 2022. Dr. Hartounian holds a Ph.D. in Chemical Engineering and a minor in Biochemistry from the University of Delaware, an M.S. in Chemical Engineering from the University of California and a B.S. in Chemical Engineering from Arya-Mehr (Sharif) University of Technology, where he was first-ranked in his class. In connection with his appointment, the C

01 Financial Statements

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Description No. 99.1 Press Release issued by Brainstorm Cell Therapeutics Inc., dated June 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: June 20, 2024 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR